It is inevitable; most men with prostate cancer, who require treatment with androgen deprivation therapy (ADT), will eventually become resistance to treatment leading to the development of metastatic disease. Men who develop metastatic castrate-resistant disease have a very poor prognosis. Historically, their overall survival is estimated only to be 24 to 36 months. A study [...]
We already know it, but the actual numbers can be a little surprising. People who have obtained the age of 60 are the most vulnerable individuals to heat waves. There are 82% to 92% more deaths than in the general population occurring in this age group. There is also a significant increase in the risk [...]
A new study links hormone therapy for prostate cancer with a higher risk of death in older men who've had serious heart problems. The side effects of hormone therapy can be significant. They include impotence, bone loss, hot flashes, memory problems, fatigue and an increased risk for diabetes and heart disease. In a study appearing [...]
Cancer Care is conducting a telephone workshop on Metastatic Prostate Cancer on Tuesday, September 22, 2009 from 1:30 to 2:30 eastern time. Listening in on the workshop is free. Participants in the workshop will be: Susan Slovin MD, PhD, Associate Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for the Treatment of Prostate & Urologic [...]
In a small trial using oral sodium clodronate, a bisphosphonate like Zometa and Fosamax, it was shown to extended prostate cancer survival by 23 percent (23%). The survival benefit was seen only when the drug was used in combination with hormone therapy in men with metastatic disease. Many doctors have believed that bisphosphonates could have [...]